Skip Content
Page Banner Image


The KINECT-HD study is investigating valbenazine for the treatment of chorea associated with Huntington disease (HD). Valbenazine has been approved by the United States Food and Drug Administration (FDA) in April 2017 for the treatment of adults with tardive dyskinesia (TD), under the trade name INGREZZA®.


KINECT-HD is a Phase 3, randomized, double-blind, placebo-controlled study. The objectives of KINECT-HD are to:

-Evaluate the efficacy of valbenazine to reduce chorea associated with HD

-Evaluate the safety and tolerability of valbenazine in subjects with HD

-Evaluate the ability of wearable movement sensors to detect changes in physical activity (optional activity)

The study is registered at and you can view the full HSG webpage regarding the study online here.

Status: Currently recruiting.

Study Type: Phase III Clinical Trial

Canadian Locations:

British Columbia
Location: University of British Columbia
Vancouver, BC  V6T 2B5
Status: Recruiting

Contact: Dr. Lynn Raymond, Study Site Investigator

Contact: Mike Adurogbangba, Study Site Coordinator

Location: North York General Hospital, Toronto
Ontario, Canada, M3B 2S7
Status: Recruiting

Contact: Dr. Philippe Rizek, Study Site Investigator

Contact: Clare Gibbons, Study Site Coordinator

Location: Ottawa Hospital Civic Site
Ontario, Canada, K1Y 4E9
Status: Recruiting

Contact: Melissa Allaire, Study Site Coordinator


For more detailed information on this study and others and for the most recent updates, please go to is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world.

Back to map

We support those facing huntington disease
 Latest Blog


Let Us Know How We Can Help
Enter your name, email address and question(s) below for assistance.



Stay in Touch!
Enter your email address below to receive occasional updates.

Newsletter Sign-up